JP2022528005A5 - - Google Patents
Info
- Publication number
- JP2022528005A5 JP2022528005A5 JP2021560478A JP2021560478A JP2022528005A5 JP 2022528005 A5 JP2022528005 A5 JP 2022528005A5 JP 2021560478 A JP2021560478 A JP 2021560478A JP 2021560478 A JP2021560478 A JP 2021560478A JP 2022528005 A5 JP2022528005 A5 JP 2022528005A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence number
- seq
- nucleic acid
- containing sequence
- vlcdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024206358A JP2025041629A (ja) | 2019-04-01 | 2024-11-27 | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962827744P | 2019-04-01 | 2019-04-01 | |
| US62/827,744 | 2019-04-01 | ||
| PCT/US2020/025936 WO2020205849A1 (en) | 2019-04-01 | 2020-03-31 | Btla-binding (cd272) antibodies for modulating immune response and treating disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024206358A Division JP2025041629A (ja) | 2019-04-01 | 2024-11-27 | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022528005A JP2022528005A (ja) | 2022-06-07 |
| JP2022528005A5 true JP2022528005A5 (enExample) | 2023-04-07 |
| JP7596298B2 JP7596298B2 (ja) | 2024-12-09 |
Family
ID=70296156
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560478A Active JP7596298B2 (ja) | 2019-04-01 | 2020-03-31 | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
| JP2024206358A Pending JP2025041629A (ja) | 2019-04-01 | 2024-11-27 | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024206358A Pending JP2025041629A (ja) | 2019-04-01 | 2024-11-27 | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11384146B2 (enExample) |
| EP (1) | EP3946622A1 (enExample) |
| JP (2) | JP7596298B2 (enExample) |
| KR (1) | KR20220047536A (enExample) |
| CN (2) | CN119735682A (enExample) |
| CA (1) | CA3135836A1 (enExample) |
| IL (1) | IL286838A (enExample) |
| WO (1) | WO2020205849A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4232480A2 (en) * | 2020-10-23 | 2023-08-30 | AnaptysBio, Inc. | B and t lymphocyte attenuator (btla) modulators and method of using same |
| JP2025501452A (ja) * | 2021-12-10 | 2025-01-22 | メルク・シャープ・アンド・ドーム・エルエルシー | ヒトメソテリン結合物質 |
| JP2025504012A (ja) * | 2022-01-29 | 2025-02-06 | ハイファイバイオ， インク． | 抗ｂｔｌａ抗体および癌治療におけるその使用 |
| KR20240139083A (ko) * | 2022-01-29 | 2024-09-20 | 하이파이바이오 인코퍼레이티드 | Btla에 대한 항체 및 이의 용도 |
| US20230322929A1 (en) * | 2022-04-12 | 2023-10-12 | Shanghai Junshi Biosciences Co., Ltd. | Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy |
| US20260035464A1 (en) * | 2022-07-19 | 2026-02-05 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2025250861A1 (en) * | 2024-05-31 | 2025-12-04 | Icahn School Of Medicine At Mount Sinai | Broadly neutralizing anti-hcmv antibodies and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US7153950B2 (en) | 2002-10-25 | 2006-12-26 | Genentech, Inc. | Nucleic acids encoding an immune related polypeptide |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| US7973138B2 (en) * | 2007-09-26 | 2011-07-05 | Genentech, Inc. | Antibodies |
| IN2012DN00863A (enExample) * | 2009-07-31 | 2015-07-10 | Medarex Inc | |
| CN107108740B (zh) | 2014-11-05 | 2021-09-17 | 豪夫迈·罗氏有限公司 | 抗fgfr2/3抗体及其使用方法 |
| JP2018521959A (ja) * | 2015-04-29 | 2018-08-09 | サンフォード−バーナム メディカル リサーチ インスティテュート | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
| EP3383908A1 (en) * | 2015-12-02 | 2018-10-10 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
| CA3013333A1 (en) | 2016-02-26 | 2017-08-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
| JP7184751B2 (ja) * | 2016-04-15 | 2022-12-06 | イミュネクスト インコーポレイテッド | 抗ヒトｖｉｓｔａ抗体およびその使用 |
-
2020
- 2020-03-31 WO PCT/US2020/025936 patent/WO2020205849A1/en not_active Ceased
- 2020-03-31 CN CN202411950244.6A patent/CN119735682A/zh active Pending
- 2020-03-31 CA CA3135836A patent/CA3135836A1/en active Pending
- 2020-03-31 US US16/836,006 patent/US11384146B2/en active Active
- 2020-03-31 KR KR1020217035131A patent/KR20220047536A/ko active Pending
- 2020-03-31 JP JP2021560478A patent/JP7596298B2/ja active Active
- 2020-03-31 CN CN202080040939.4A patent/CN114585416B/zh active Active
- 2020-03-31 EP EP20720302.7A patent/EP3946622A1/en active Pending
-
2021
- 2021-09-30 IL IL286838A patent/IL286838A/en unknown
-
2022
- 2022-07-10 US US17/811,586 patent/US20230340123A1/en active Pending
-
2024
- 2024-11-27 JP JP2024206358A patent/JP2025041629A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7386277B2 (ja) | 二重特異性シグナル伝達物質およびその使用 | |
| US20240025980A1 (en) | Therapeutic targeting of non-cellular structures | |
| US12497436B2 (en) | Chimeric protein, and encoding nucleic acid thereof, comprising interferon-β and a targeting moiety comprising a single-domain antibody or single-chain antibody | |
| US20260115254A1 (en) | Immune-cell targeted bispecific chimeric proteins and uses thereof | |
| US20240368277A1 (en) | SIRP1a TARGETED CHIMERIC PROTEINS AND USES THEREOF | |
| US20200069797A1 (en) | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists | |
| US20210261668A1 (en) | Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1 | |
| US20210024631A1 (en) | Bi-functional proteins and construction thereof | |
| AU2024202552A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| US20260109748A1 (en) | Modulation of dendritic cell lineages | |
| IL269387A (en) | Pan-elr cxc chemokine antibodies | |
| US20240199714A1 (en) | Il-2 based constructs | |
| JP2022537289A5 (enExample) | ||
| US20230002493A1 (en) | Pd-l1 targeted chimeric proteins and uses thereof | |
| JP2022522815A5 (enExample) | ||
| AU2016330471A1 (en) | Antibodies that bind human cannabinoid 1 (CB1) receptor | |
| TW202539734A (zh) | 使用白細胞介素-17（il-17）拮抗劑治療自體免疫性疾病之方法 | |
| WO2017221174A1 (en) | Methods of treating vitiligo using interleukin-17 (il-17) antibodies | |
| JP2022534494A5 (enExample) | ||
| US20240400633A1 (en) | Split human ifn-gamma and tnf-alpha constructs and uses thereof | |
| CN116059377A (zh) | 抗ox40抗体在联合用药中的应用 | |
| WO2024240247A1 (en) | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 antibodies | |
| JP2022520817A5 (enExample) | ||
| JP2024074278A (ja) | Ｌａｇ－３およびｐｄ－１／ｌａｇ－３抗体 |